Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.
Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.
Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.
Apellis Pharmaceuticals announced promising results from the 24-month Phase 3 OAKS study of pegcetacoplan for treating geographic atrophy (GA) related to age-related macular degeneration (AMD). New analyses revealed that patients receiving pegcetacoplan treatments, both monthly and every-other-month, exhibited improved visual function near GA lesion borders compared to sham treatments. The data supports pegcetacoplan's potential as the first effective therapy for GA, aiming for regulatory submissions to the European Medicines Agency and a PDUFA target action date of November 26, 2022, in the U.S.
Apellis Pharmaceuticals (APLS) announced four oral presentations at the AAO Annual Meeting regarding pegcetacoplan for treating geographic atrophy (GA) due to age-related macular degeneration. The presentations will cover 24-month safety and efficacy results from Phase 3 DERBY and OAKS studies. The FDA has granted Priority Review for pegcetacoplan, with a target action date of November 26, 2022. The company plans to submit a marketing authorization application to the European Medicines Agency by year-end.
Apellis Pharmaceuticals (Nasdaq: APLS) announced an updated timing for its fireside chat at the Bank of America Global Healthcare Conference. The chat is scheduled for September 16, 2022, at 9:55 a.m. BST / 4:55 a.m. ET. This event will be accessible via a live webcast on the company's website. Apellis is recognized for its innovative work in complement medicine, having introduced the first targeted C3 therapy in 15 years to treat rare, retinal, and neurological diseases.
Apellis Pharmaceuticals announced the approval of equity awards for 64 new employees on September 1, 2022. The awards consist of options for 12,500 shares and 113,372 restricted stock units (RSUs). The options have an exercise price of $63.58, the closing price on the grant date. Vesting for the options occurs over four years, while RSUs vest at 25% annually. These grants are part of Apellis' 2022 Inducement Stock Incentive Plan and are crucial for employee retention. This announcement signifies Apellis' commitment to recruiting top talent in the biopharmaceutical sector.
Apellis Pharmaceuticals (Nasdaq: APLS) will participate in several investor conferences in September 2022. Notable events include the Citi 17th Annual BioPharma Conference on September 7 at 1:00 p.m. ET, the Wells Fargo Healthcare Conference on September 8 at 1:55 p.m. ET, the Baird 2022 Global Healthcare Conference on September 14 at 3:10 p.m. ET, and the BofA Global Research Healthcare Conference on September 16 at 10:05 a.m. ET. Webcasts will be available on their website for 30 days post-event.
Apellis Pharmaceuticals announced positive 24-month data from Phase 3 DERBY and OAKS studies on pegcetacoplan for geographic atrophy (GA) linked to age-related macular degeneration (AMD). Treatment effects accelerated between months 18-24, with notable reductions in GA lesion growth: DERBY showed 36% (monthly) and 29% (every-other-month), while OAKS reported 24% (monthly) and 25% (EOM) reductions. The drug maintained a favorable safety profile, with no significant adverse events. A potential first approval in the U.S. is expected by Nov. 26, 2022, with European submission planned by year-end.
Apellis Pharmaceuticals (APLS) announced significant updates in its Q2 2022 report, achieving $15.7 million in U.S. net revenue from EMPAVELI. The company received FDA acceptance for a New Drug Application for pegcetacoplan targeting geographic atrophy, with a review target date of November 26, 2022. Cash and investments totaled $852.8 million as of June 30, 2022, ensuring a runway into Q1 2024. Notably, Apellis also initiated a Phase 3 study for IC-MPGN and C3G, marking a transformative period for the company, as it advances multiple therapeutic programs.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced the grant of equity awards to two new employees as of August 1, 2022. These equity inducement awards are outside of the company's 2017 Stock Incentive Plan, aligning with the terms of the 2022 Inducement Stock Incentive Plan. Each employee received options for 2,409 restricted stock units (RSUs), which will vest at 25% annually over four years, contingent upon continued employment. This initiative is part of Apellis' strategy to attract top talent in the biopharmaceutical sector.
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call on August 8, 2022, at 4:30 p.m. ET to discuss its second quarter 2022 financial results. Investors can pre-register for the live call and access a webcast with accompanying slides on the company's website. Apellis is recognized for its leadership in complement therapeutics, having introduced the first new class of complement medicine in 15 years. The company aims to develop transformative therapies for rare, retinal, and neurological diseases.
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) announced on July 27, 2022, the completion of privately negotiated exchange agreements involving its 3.500% Convertible Senior Notes due 2026. Approximately $65.9 million of these Notes will be exchanged for 2,036,886 shares of common stock, while another $9.7 million will be swapped for additional shares based on a calculated valuation. The transactions are set to close by August 1, 2022, contingent on customary conditions. Notably, the shares issued will not be registered under the Securities Act, limiting their sale.
FAQ
What is the current stock price of Apellis Pharmace (APLS)?
What is the market cap of Apellis Pharmace (APLS)?
